Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the ...

In late March 2026, Novavax appointed Dr. Robert Walker as Executive Vice President and Head of R&D, while activist investor Shah Capital renewed its campaign to overhaul the company’s board, ...

Activist investor Shah Capital is renewing its pressure campaign against Novavax (NVAX) as it looks to vote against the re-election of the company’s board nominees and its executive ​compensation ...

Chief among its criticisms is Novavax's failure to build sales of its protein-based COVID-19 vaccine Nuvaxovid/Covovax, a ...

In the latest close session, Novavax (NVAX) was up +1.31% at $8.53. The stock outperformed the S&P 500, which registered a daily gain of 0.62%. Meanwhile, the Dow gained 0.58%, and the Nasdaq, a ...

Shah Capital, which has agitated for change at the vaccine maker for years, is calling on fellow shareholders to end what it ...

"Your tenure has overseen a DESTRUCTION of shareholder value—a direct result of chronic operational shortcomings and failures ...

After shedding expensive commercial infrastructure and pivoting to a partnership model, the company is now positioning its ...

Shah Capital plans “against” votes on directors and say-on-pay, while seeking to sway ISS and Glass Lewis rather than running ...

Following its emergency authorization last month, just 7,300 doses of Novavax's COVID-19 vaccine have been administered to Americans across the country, newly updated data from the Centers for Disease ...